RNA: The new revolution in nucleic acid vaccines

被引：140

作者：

Geall, Andrew J. ^{[1
]}

Mandl, Christian W. ^{[1
]}

Ulmer, Jeffrey B. ^{[1
]}

机构：

[1] Novartis Vaccines & Diagnost, Cambridge, MA 02139 USA

来源：

SEMINARS IN IMMUNOLOGY | 2013年 / 25卷 / 02期

关键词：

Replicon; Manufacturing; Safety; Stability; Human; REVERSE CAP ANALOGS; RABIES VIRUS GLYCOPROTEIN; CYTOTOXIC T-LYMPHOCYTES; MODIFIED MESSENGER-RNA; INFLUENZA-A VIRUS; IMMUNE-RESPONSES; ALPHAVIRUS VECTORS; DNA VACCINES; IN-VIVO; DIRECT-INJECTION;

D O I：

10.1016/j.smim.2013.05.001

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Nucleic acid vaccines have the potential to address issues of safety and effectiveness sometimes associated with vaccines based on live attenuated viruses and recombinant viral vectors. In addition, methods to manufacture nucleic acid vaccines are suitable as generic platforms and for rapid response, both of which will be very important for addressing newly emerging pathogens in a timely fashion. Plasmid DNA is the more widely studied form of nucleic acid vaccine and proof of principle in humans has been demonstrated, although no licensed human products have yet emerged. The RNA vaccine approach, based on mRNA and engineered RNA replicons derived from certain RNA viruses, is gaining increased attention and several vaccines are under investigation for infectious diseases, cancer and allergy. Human clinical trials are underway and the prospects for success are bright. (c) 2013 Elsevier Ltd. All rights reserved.

引用

页码：152 / 159

页数：8

共 120 条

[41] Synthesis of novel mRNA 5′ cap-analogues:: Dinucleoside P1, P3-tri-, P1, P4-tetra-, and P1, P5-pentaphosphates [J].

Jemielity, J ;

Stepinski, J ;

Jaremko, M ;

Haber, D ;

Stolarski, R ;

Rhoads, RE ;

Darzynkiewicz, E .

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2003, 22 (5-8) :691-694

[42] Novel "anti-reverse" cap analogs with superior translational properties [J].

Jemielity, J ;

Fowler, T ;

Zuberek, J ;

Stepinski, J ;

Lewdorowicz, M ;

Niedzwiecka, A ;

Stolarski, R ;

Darzynkiewicz, E ;

Rhoads, RE .

RNA, 2003, 9 (09) :1108-1122

[43] Sensing of RNA Viruses: a Review of Innate Immune Receptors Involved in Recognizing RNA Virus Invasion [J].

Jensen, Soren ;

Thomsen, Allan Randrup .

JOURNAL OF VIROLOGY, 2012, 86 (06) :2900-2910

[44] Immunomodulatory Effects of dsRNA and Its Potential as Vaccine Adjuvant [J].

Jin, Bo ;

Sun, Tao ;

Yu, Xiao-Hong ;

Liu, Chao-Qun ;

Yang, Ying-Xiang ;

Lu, Ping ;

Fu, Shan-Feng ;

Qiu, Hui-Bin ;

Yeo, Anthony E. T. .

JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2010,

[45] A SINDBIS VIRUS MESSENGER-RNA POLYNUCLEOTIDE VECTOR ACHIEVES PROLONGED AND HIGH-LEVEL HETEROLOGOUS GENE-EXPRESSION IN-VIVO [J].

JOHANNING, FW ;

CONRY, RM ;

LOBUGLIO, AF ;

WRIGHT, M ;

SUMEREL, LA ;

PIKE, MJ ;

CURIEL, DT .

NUCLEIC ACIDS RESEARCH, 1995, 23 (09) :1495-1501

[46] Intradermal Electroporation of Naked Replicon RNA Elicits Strong Immune Responses [J].

Johansson, Daniel X. ;

Ljungberg, Karl ;

Kakoulidou, Maria ;

Liljestrom, Peter .

PLOS ONE, 2012, 7 (01)

[47] Long-term storage of DNA-free RNA for use in vaccine studies [J].

Jones, Kathryn L. ;

Drane, Debbie ;

Gowans, Eric J. .

BIOTECHNIQUES, 2007, 43 (05) :675-681

[48] Suppression of RNA recognition by Toll-like receptors:: The impact of nucleoside modification and the evolutionary origin of RNA [J].

Karikó, K ;

Buckstein, M ;

Ni, HP ;

Weissman, D .

IMMUNITY, 2005, 23 (02) :165-175

[49] Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability [J].

Kariko, Katalin ;

Muramatsu, Hiromi ;

Welsh, Frank A. ;

Ludwig, Janos ;

Kato, Hiroki ;

Akira, Shizuo ;

Weissman, Drew .

MOLECULAR THERAPY, 2008, 16 (11) :1833-1840

[50]

Karikó K, 2007, CURR OPIN DRUG DISC, V10, P523

← 1 2 3 4 5 6 7 8 9 10 →